1743 / 1835
Points for discussion
•
IPI=1, aaIPI=1,
low risk
group
•
Bulky
early stage require full course chemo (not eligible for abbreviated
chemo + RT)
•
CHOP-
14
is superior to CHOP-
21
, the same is not true when Rituximab is
added. A large phase 3 randomised study showed that there was no
difference between RCHOP-21 and RCHOP-14
(Cunningham, Lancet 2013).
•
8
cycles have not been found to be better than
6
cycles
(Pfreundschuh,
Lancet 2008).
•
RT for bulky site
: most likely site of recurrence. Evidence from German
trials. IELSG-37 testing PET-guided RT.
•
MDM: RCHOPx6 + ISRT with close monitoring of response on PET/CT